68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer
- 7 June 2016
- journal article
- clinical trial
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 192 (7) , 431-439
Abstract
The goal of this work was to evaluate the early efficacy of 68Ga-PSMA ligand PET/CT imaging for radiotherapy of locally recurrent and/or oligometastatic prostate cancer. A total of 29 patients with biochemical recurrence received a 68Ga-PSMA ligand PET/CT for restaging of disease, followed by 3D conformal radiotherapy of metastases or intensity-modulated radiation therapy of the prostate bed. Prostate-specific antigen (PSA) levels and imaging procedures served as the reference standard to assess the treatment efficacy. PET/CT was positive in 96.6% of patients and revealed that 13.8% of patients had locally recurrent disease, 58.6% had isolated lymph node metastases, 20.7% had isolated bone metastases, and 3.4% showed lymph node metastases and a vertebral metastasis. The median follow-up was 8.3 months (range 3.0–17.3 months). The median PSA prior to radiotherapy was 1.47 ng/ml (range 0.52–32.01 ng/ml) and showed a statistically significant decrease to 0.58 ng/ml (range < 0.07 to 6.33 ng/ml, p < 0.001). Two patients (6.8%) developed progressive disease outside the radiation field after 12.0 and 12.7 months, yielding a local control rate of 100% at the median follow-up. No grade III acute toxicity or late toxicity grade II was observed. Only 2 patients (6.8%) reported persisting grade I diarrhoea according to the LENT-SOMA criteria 3 months after radiotherapy. Deterioration of the urinary or faecal continence was not observed. Preliminary results in the presented cohort suggest that radiotherapy based on 68Ga-PSMA ligand PET/CT yields effective local control and significant treatment response in terms of PSA levels in the absence of clinically important side effects. Furthermore, this approach delayed the necessity of androgen deprivation therapy or systemic therapy.Keywords
This publication has 35 references indexed in Scilit:
- A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancerNuclear Medicine Communications, 2013
- The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2013
- Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancerFrontiers in Oncology, 2013
- Salvage Lymph Node Dissection with Adjuvant Radiotherapy for Nodal Recurrence of Prostate CancerJournal of Urology, 2012
- Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Duration of First Off-Treatment Interval Is Prognostic for Time to Castration Resistance and Death in Men With Biochemical Relapse of Prostate Cancer Treated on a Prospective Trial of Intermittent Androgen DeprivationJournal of Clinical Oncology, 2010
- Choline PET based dose-painting in prostate cancer - Modelling of dose effectsRadiation Oncology, 2010
- [11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate CancerUrologia Internationalis, 2008
- Treatment failure after primary and salvage therapy for prostate cancerCancer, 2007
- Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?Journal of Clinical Oncology, 2005